#
Microskin
my account
cart
Investors

Microskin Continues to Expand Worldwide Network

with First Clinics Opening in Canada, India and the Middle East

 

Microskin’s world-first simulated second skin assists people with vitiligo, birthmarks, burns, eczema, and other skin-related conditions

 

LONDON and BRISBANE, Australia , May 24, 2016 – Microskin plc (MLSKN:Euronext Paris) announced today the continued expansion of the company’s worldwide network of clinics with the opening of licensed clinics in Canada, India and the Middle East.  Bringing the total to nine clinics around the world that offer a personalized solution to create a color-matched, waterproof ‘second skin’ to conceal or camouflage skin conditions.  The six other clinics are located in Australia, Estonia, New Zealand, Turkey, and the United States.

 

“The great need for our world-leading second skin product has propelled the expansion of Microskin’s worldwide network of clinics to Canada, India and the Middle East,” said Barry Amor, chairman of Microskin plc. “People around the world are searching for second skin solutions for something as simple as camouflaging a tattoo to the profound effect of covering noticeable skin conditions like vitiligo, allowing our clients to feel like themselves again.”

 

Since the opening of its first clinic in Brisbane in 2005, Microskin has assisted people from all over the world with skin-related conditions, including vitiligo, birthmarks, burns, eczema, lupus, and keloid scarring.  Vitiligo is a condition where the skin loses color in blotches.  Different than heavy foundations or makeup, Microskin’s second skin does not rub off, allows skin to breathe, and lasts several days. 

 

“Microskin’s superior color correction system is individually formulated to each person’s skin, so our clients feel confident in their appearance and are pleased with how it feels and how long it lasts.” continued Mr. Amor. “We are especially pleased to have a licensed clinic opening in India, which has the largest population of people per capita with vitiligo.”

 

The first clinic in India is expected to open in Coimbatore by the end of the summer, with multiple clinics opening across the subcontinent in the next three years.  The first licensed Microskin clinic in Canada will be located in Toronto and is expected to open in June.  In the Middle East, Microskin has completed training with the National Center for Vitiligo and Psoriasis, and the first clinic is expected to open in Riyadh, Saudi Arabia in June. 

 

About Microskin plc

 

Founded in 2005, Microskin plc is a public company that develops simulated second skin for a variety of cosmetic and medical uses.  Microskin’s simulated second skin is the world-leading product that combines years of cosmetic chemistry research with a proprietary color-matching software.  Because Microskin’s second skin does not rub off, it is water-resistant and lasts for several days.  Each client receives an individualized product kit that can easily be applied at home. The company has licensed clinics in Australia, Canada, Estonia, India, the Middle East, New Zealand, India, Turkey, and the United States.  For more information, please visit http://www.microskin.com.au/.

 

MEDIA CONTACT: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

 

SOURCE: Microskin, plc

 

 


 [JY1]If the company is HQ’d in the UK, you may consider adding London – if that is the city where the HQs are located.  London is one of the handful of cities that does not require a country.  http://writingexplained.org/ap-style/ap-style-datelines

Click here to download the Microskin Plc-GM Proxy Card

Microskin plc: Change to Effective Date of Share Sub-Division

15 March 2016

 

Share Sub-Division to Take Effect from 6pm (GMT) on 17 March 2016

 

Microskin plc (the "Company") wishes to inform the market that the sub-division of its ordinary shares will now take effect from 6pm (GMT) on Thursday, 17 March 2016.  The change is necessary to accommodate the operational requirements of relevant market parties and systems.

 

Following the sub-division, the Company’s €0.12 ordinary shares will begin trading on the Marché Libre market of Paris Euronext on 18 March 2016. The crediting, as applicable, of the B shares to CREST stock accounts is expected to occur on 18 March 2016, and their recognition within Euroclear France is expected to occur on 22 March 2016.

 

The Company thanks its shareholders for their patience and looks forward to having all market arrangements for its shares in place early next week.

 

 

Issued by

 

Barry Amor

Executive Chairman

Microskin plc

 

Contact

271a Rode Road

Wavell Heights  Qld 4012

 

p: +61732606125 f +61732606295

w: www.microskin.com.au

e: bamor@microskin.com.au

 

 

The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein.

 

 

 

 

Microskin plc : All resolutions [unanimously] passed at adjourned GM on 10 March 2016

10 March 2016

 

Adjourned General Meeting 10 March 2016

 

Microskin plc (the "Company") wishes to inform the market that the Company held its adjourned general meeting of shareholders at 6.00pm (Brisbane Time) at 217A Rode Road, Wavell Heights, Brisbane, 4012 QLD, Australia on 10 March 2016 (the “General Meeting”).

 

All resolutions set out in the notice of meeting dated 12 February 2016 and put to the General Meeting were passed unanimously by the shareholders present in person or by proxy and represented at the meeting. The Company is pleased to confirm that a total of 12,299,900 votes were cast in favour of all resolutions, making up over 85% of all votes that could have been cast.

 

Pursuant to the first resolution as amended by ordinary resolution at the General Meeting, each of the Company’s ordinary shares of €1.20 will be sub-divided on a ten-to-one basis into one new ordinary share of €0.12 (“New Ordinary Share”) and nine B ordinary shares of €0.12 each (“B Shares”) with effect from 6pm (GMT) on 15 March 2016 unless the directors reasonably determine a later date in the interests of an orderly market.  As of that time, the Company’s share capital will be made up of 14,362,965 New Ordinary Shares and 129,266,685 B Shares.

 

The New Ordinary Shares and the B Shares will have the same rights as the pre-division ordinary shares, except that the B Shares will only be transferable through off-market trades and will have no right to dividends for twenty-four months after issue. At the end of that period, the B Shares will convert automatically into New Ordinary Shares and the directors expect that they will be admitted to trading on the Marché Libre market of Paris Euronext (“Marché Libre”). 

 

The New Ordinary Shares will be tradeable on Marché Libre with the same ISIN as the pre-division ordinary shares, and the validity of existing share certificates will be unaffected. The opening market price of the New Ordinary Shares will be equal to one-tenth of their closing price on the effective date. 

 

B Shares resulting from the sub-division of existing ordinary shares held through the CREST system will be issued in dematerialized form and no share certificates will be issued in respect of them.  ISIN number GB00BYZ0C406 has been assigned to the B Shares, which are expected to be credited, as applicable, to CREST stock accounts on 16 March 2016 (assuming the share sub-division is effective the preceding day).

 

B Shares resulting from the sub-division of certificated ordinary shares will be issued in certificated form, and share certificates will be sent to shareholders by no later than 14 days following the meeting date.

 

The General Meeting also approved the issue of preference shares of €0.12 each (“Preference Shares”) which are entitled to receive a cumulative preferential dividend in each of the first two years following issue, and authorised the directors to determine the amount of that dividend provided it does not exceed €0.05 in each year.  Pursuant to the resolutions, the Preference Shares will be converted into New Ordinary Shares on the later of the date that is 24 months after the first date of issue and the date on which the preferential dividend has been paid in full.

 

During 2016, the Company expects to undertake a private placement of approximately 10 million Preference Shares for targeted proceeds of approximately €2,000,000.

 

The General Meeting also confirmed authorities relating to the allotment of shares as given at the Company’s 2015 Annual General Meeting, and approved the adoption of new articles of association for the Company setting out the rights and restrictions applicable to the New Ordinary Shares, the B Shares and the Preference Shares.

 

Issued by

 

Barry Amor

Executive Chairman

Microskin plc (“the Company”)

 

Contact

271a Rode Road

Wavell Heights

Brisbane

Qid Australia 4012

 

p:+617 3260 6125 | f: +617 3260 6295

w: www.microskin.com.au

e: bamor@microskin.com.au

The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein.

 

 

 

 

 

 

Microskin plc : Change Regarding Proposed B Ordinary Shares

10th March 2016

 

B Ordinary Shares to be Issued in Uncertificated Form

 

Microskin plc (the "Company") wishes to inform the market that, as a result of its discussions with Euronext and Euroclear regarding the mechanics of the Company’s proposed share sub-division, the B ordinary shares (“B Shares”) resulting from the sub-division (if approved) of existing ordinary shares held through the CREST system will be issued in dematerialized form and no share certificates will be issued in respect of them.  

 

A new ISIN number has been assigned in respect of the B Shares, which will be announced following the adjourned General Meeting of the Company on 10 March 2016 provided the share sub-division is approved. The crediting, as applicable, of B Shares to CREST stock accounts is expected to occur on 16 March 2016 (assuming the share sub-division is effective the preceding day).

 

The decision to issue B Shares in uncertificated form is intended to ensure that shareholders who hold their existing ordinary shares through Euroclear France will receive their shares in an orderly fashion.

 

B Shares resulting from the sub-division of certificated ordinary shares will be issued in certificated form, and share certificates will be sent to shareholders by no later than 14 days following the meeting date, as set out in the Notice of General Meeting dated 12 February 2016.

 

Issued by

 

Barry Amor

Executive Chairman

Microskin plc (“the Company”)

 

Contact

271a Rode Road

Wavell Heights

Brisbane Qld Australia 4012

 

p: +617 3260 6125 | f: +617 3260 6295

w: www.microskin.com.au

e: bamor@microskin.com.au

 

 

The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein

 

Microskin plc : Proposed Amendment to Resolution 1

9th March 2016

 

Proposed Change to Effective Date of Share Sub-Division

 

Microskin plc (the "Company") wishes to inform the market that it has received written notice from a shareholder of a proposed amendment to Resolution 1 as set out in the Notice of General Meeting dated 12 February 2016.

 

Pursuant to the proposed amendment, the effective time of the share sub-division (assuming that it is approved at the Company’s adjourned General Meeting on 10 March 2016) would be changed from 6pm (GMT) on the resolution date to 6pm (GMT) on 15 March 2016 (or such later date as the directors may reasonably determine in the interests of an orderly market).  The reason for the proposed amendment is stated to be to ensure that the relevant market parties and systems are fully ready to process the new ordinary shares and B ordinary shares resulting from the share sub-division.

 

Resolution 1 is proposed as an ordinary resolution and may be amended by ordinary resolution in accordance with the Company’s articles of association.

 

Issued by

 

Barry Amor

Executive Chairman

Microskin plc (“the Company”)

 

Contact

271a Rode Road

Wavell Heights

Brisbane Qld Australia 4012

 p: +6173260 6125  f: +6173260 6295

w: www.microskin.com.au

e: bamor@microskin.com.au

 

 The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein.

 

 

Microskin PLC : Adjournment of GM to 10 March 2016

3 March 2016

 

General Meeting 3rd March 2016 –Adjournment

 

Microskin plc (the "Company") wishes to inform the market that, as announced yesterday, the general meeting (the “General Meeting”) of shareholders held at 6.00pm (Brisbane Time) was adjourned for a period of seven days.

 

The adjourned General Meeting will now be held at 6.00pm (Brisbane Time) at 217A Rode Road, Wavell Heights, Brisbane, 4012 QLD, Australia on 10 March 2016. The conference details for the General Meeting will remain the same.

 

Your PIN is:                17333045       

           

Your Service Number is:                     1800 064278*

(Domestic Access Only)

 

Metered Access:                                             07 30257501

International Access:  (Int. Access Code)      + 617 30257501

 

Toll free Canada                       1866 2100923

Toll free France                           0800915512

Toll free Germany                       0800 1825041

Toll free UK *                              0800 7319097

Toll free USA                             1888 8579107

 

 

Issued by

 

Barry Amor

Executive Chairman

Microskin PLC

 

Contact

 

 

 271a Rode Road

Wavell Heights

Brisbane

Qld Australia 4012

p: 617 3260 6125  f: 617 3260 6295

w: www.microskin.com.au

e: bamor@microskin.com.au

 

The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein.

 

 

 

 

 

 

Microskin PLC : GM on 3rd March 2016 to be adjourned

2 March 2016

 

General Meeting 3rd March 2016 – Planned Adjournment

 

Microskin plc (the "Company") wishes to inform the market that it is expected that the general meeting of shareholders to be held at 6.00pm (Brisbane Time) at 217A Rode Road, Wavell Heights, Brisbane, 4012 QLD, Australia on 3rd March 2016 (the “General Meeting”) will be adjourned.

 

It is expected that the General Meeting will be adjourned for a period of seven days and the adjourned meeting will be held at the same time and location on 10 March 2016.

 

The Company has been in discussions with Euronext and Euroclear regarding the mechanics of the share sub-division and the consequences for those shareholders who hold shares through Euroclear. Unfortunately it has not been possible to resolve these discussions prior to the General Meeting and therefore the board believes that it is in the best interests of the shareholders to adjourn the General Meeting, so that the shareholders will be able to consider the proposed resolutions in light of all relevant information.

 

The General Meeting will still be opened as planned on 3 March 2016, but as the first item of business, the Chair will propose that the General Meeting is adjourned for a period of seven days. Assuming this adjournment is accepted by the meeting, the General Meeting will then be immediately adjourned.

 

Any proxies submitted in respect of the General Meeting will remain valid in respect of the adjourned General Meeting.

 

 

Issued by

 

Barry Amor

Executive Chairman

Microskin PLC

 

Contact

 271a Rode Road

Wavell Heights

Brisbane

Qld Australia 4012

p: 617 3260 6125  f: 617 3260 6295

w: www.microskin.com.au

e: bamor@microskin.com.au

 

The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein.

 

 

 

 

12th January 2016

THE MICROSKIN GROUP ANNOUNCES INTENTION TO CARRY OUT A TEN-FOR-ONE STOCK SPLIT

Subject to the approval of the shareholders at a General Meeting of Microskin plc (the “Company”), the Board of Directors has decided in principle that each ordinary share of €1.20 in the Company should be sub-divided into one ordinary share of €0.12 and nine B ordinary shares of €0.12 each (the “B Shares”). 

The B Shares will have the same rights as the ordinary shares, but they will not carry any rights to dividends and they will not be listed on the Marché Libre market of the Paris Euronext. The B Shares will be freely transferable, but only through off-market transfers. 24 months after the sub-division, it is intended that the B Shares will be converted into ordinary shares and admitted to trading on the Marché Libre market of the Paris Euronext. 

The Company is expecting to undertake a significant capital raising in 2016 through the issue of preference shares of €0.12 each to investors. The Company is hoping to raise approximately €2,000,000 through this process. The stock split is intended to ensure that existing shareholders are not disadvantaged through excessive dilution of their holdings in the course of that capital raising and it is also intended to help protect the listed share price of the Company following the capital raising.

The capital raising will also allow the Company to open company owned clinics in key locations, expand the direct to end user sales channel and carry out clinical trials on the other applications of Microskin. Further information will be provided on the capital raising in due course.

After the stock split, the Company’s share capital will be made up of 14,362,965 ordinary shares of €0.12 each and 129,266,685 B ordinary shares of €0.12 each.

The Company is in the process of drafting a formal notice setting out the shareholder resolutions required to approve the above steps and this will be published as soon as reasonably possible.

Contact: Barry Amor

Email:  bamor@microskin.com.au

Microskin plc : All resolutions unanimously passed at AGM 2015
 

2015 Year End Report

29th December 2015

 

Annual General Meeting 2015

 

Microskin plc (the "Company") wishes to inform the market that the Company held its annual general meeting of shareholders at 6.00pm (Australian Eastern Standard Time) at 217A Rode Road, Wavell Heights, Brisbane, 4012 QLD, Australia on the 29th December 2015.

All resolutions as set out in the notice dated 1st December 2015 and put to the Annual General Meeting 2015 were passed unanimously by the shareholders present in person or by proxy and represented at the meeting.  

Issued by

Barry Amor

Executive Chairman

Microskin plc (“the Company”)

Contact

271a Rode Road

Wavell Heights

Brisbane

Qld Australia 4012

p: 617 3260 6125  f: 617 3260 6295

w: www.microskin.com.au

e: bamor@microskin.com.au

The issuers of this announcement warrant that they are solely responsible for the content, accuracy and originality of the information contained therein.

28th July 2015 -  Acquisition of Mobilespectra Pty Ltd

Microskin plc (GXG:MSKN) (the “Company”) is pleased to announce that it has recently completed the acquisition of Mobilespectra Pty Ltd in consideration of the issue of 5,325,279 ordinary shares in the capital of the Company. The authority to allot these shares was unanimously approved by the shareholders voting at the recent General Meeting of the Company.

Prior to the application of Microskin, the patients skin colour must be analysed so that Microskin can be custom developed to match the users natural skin tone. This matching process is presently being undertaken in clinics using expensive equipment and software supplied by a third party. Patient records (including colour matching information) are subsequently uploaded to the central Microskin ™ database available for all future patient product orders

By acquiring Mobilespectra, Microskin will benefit significantly through use of their colour matching software application (which is designed for use on a smart phone). Not only will the app be used in clinics to replace the existing third party software and equipment, but it can also be downloaded via the internet and used directly by the consumer to accurately determine their own individual skin tone. Following completion of successful trialling which is already underway, acquisition of ownership rights and official launch of the software, Microskin customers will no longer be required to physically visit an approved Microskin clinic in order to be colour assessed.

It is expected that the acquisition will significantly expand the potential accessible market of Microskin™ particularly in the online retail market.

The Company can also confirm that 112,990 shares were recently surrendered by mutual consent and are currently held by the Company.

As a result, there are currently 14,362,965 ordinary shares in issue in the capital of the Company, 112,990 of which are held by the Company and are nil paid.

General Meeting 14 July 2015

Microskin plc (GXG:MSKN) (the "Company") wishes to inform the market that the Company held a general meeting of shareholders at 9.00am BST at Grosvenor House Hotel, 86-90 Park Lane, London W1K 7TN, on the 14 July 2015.

All resolutions as set out in the notice dated 19th June 2015 and put to the General Meeting were passed unanimously by the shareholders present in person or by proxy and represented at the meeting.

Issued by 
Barry Amor 
Executive Chairman
Microskin plc ("the Company")

Contact Barry Amor's office
c/o Microskin International Pty Ltd, Australia

Tel +617 32606125

email bamor@microskin.com.au 

 

 

 

 

Notice of conversion of a debt to shares-    2nd July 2015 

Microskin plc (the “Company”) are pleased to confirm that a debt of AUS$ 536,833.19 owed by the Company to Skiptrak Pty Ltd has been fully converted into ordinary shares of the Company at a price of €2.10 per share. As a result 175,069 ordinary shares were allotted to the nominee of Skiptrak Pty Ltd as of 23 June 2015.

 This allotment brings the total number of issued ordinary shares in the Company to 9,037,686 and the total number of shares beneficially held by Skiptrak Pty Ltd to 708,716.

 Skiptrak Pty Ltd is beneficially owned by Barry Amor, the Executive Chairman of Microskin plc

For further information you can contact us on bamor@microskin.com.au

22nd June 2015

22nd December 2014


Please click on the below link to view the audited accounts for the financial year to 30th June 2014.

30th November 2014

Microskin PLC
Audited Accounts for Financial Year Ended 30th June 2014

Shareholders should be advised that the audited accounts for the financial year to 30th June 2014 will be published on the company website on or before the 20th December 2014.

Any queries or concerns should be directed to Barry Amor: Executive Chairman at bamor@microskin.com.au

14th August 2014

Confirmation letter was received from GXG - Readmitted to the GXG Maket by joining the GXG Main Quote

 

17th March 2014

Results of Annual General Meeting

Microskin PLC (GXG:MSKN) (the "company") wishes to inform the market that the Company held its annual general meeting of shareholders at  The Boardroom, 1 Berkeley Street, Mayfair, London W1J 8DJ United Kingdom at 10:00 hours (GMT) on the 14th March 2014.

The results of the meeting are as below

Removal from the GXG

Following members approval at the AGM for the Company's removal from the First Quote Exchange, the Company has today given notice to GXG that the Company wishes to be removed from GXG on 15th April 2014, being 21 business days from the date of notice as per Listing Rule 13.1

Resignation of Company Secretary

The Company wishes to inform the Market that David Mahon has resigned as Company Secretary effective today, 17th March 2014 the Company will appoint a replacement in due course.

For further information about this update contact

Barry Amor Tel: +61 7 3260 6125

MEDIA RELEASE

9th August 2013

 

Microskin announces patent to be granted in the US

 

Microskin PLC (GXG: MSKN), a revolutionary second skin technology company, announced today that it has received advice from the US Patent and Trademark Office that their patent will be granted.

The company produces a simulated second skin individually formulated to colour correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin PLC’s wholly owned subsidiary, Microskin International, has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says the patent marks a major milestone in overseas expansion for Microskin PLC.

“This patent will protect our intellectual and material property within Microskin PLC, excluding others from making, using, offering for sale, selling or importing our product throughout the US,” Mr Amor says.

“Receiving a patent for Microskin in the US ensures our hard work and years of research are respected in the industry.

 

“We believe the US patent will assist in the granting of patents in China and Australia, with patents already approved in Canada, India and New Zealand.”

 

Statistics show the average time for patent applications to be processed in the US in 2012 was 2.7 years.

 

“We have been at the forefront of research and development of a second skin-technology, so to be granted this patent after such rigorous processing is a great achievement for Microskin,” Mr Amor says.

 

The US is already home to two Microskin clinics in New York and California.

 

 

 

 

 

MEDIA RELEASE

25 July 2013

 

Microskin granted approval from Saudi FDA

 

Microskin PLC (GXG: MSKN), a revolutionary second skin technology company, has received approval from the Saudi FDA to import its product allowing operations to commence immediately in Riyadh, Saudi Arabia.

 

The company produces a simulated second skin individually formulated to color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin PLC’s wholly owned subsidiary, Microskin International, has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says approval from the Saudi FDA marks a major milestone for Microskin’s development in the Middle East, as FDA process’ can take up to five years to complete.

“The Middle East has a high incidence of vitiligo and other skin conditions, so receiving approval from the Saudi FDA provides us with a great opportunity to reach new clients and provide them with effective solutions for their skin issues,” Mr Amor says.

“Our agreement with The Light Clinic in Riyadh, which is considered to be one of the largest vitiligo treatment centres in the world, will see that Microskin is available to approximately 18,000 patients and eight sister clinics.

“We intend to use this momentum to investigate other franchising options in Jedda followed by Dubai.”

The overseas expansion of Microskin in the Middle East has furthered the company’s geographic reach, capturing new markets that weren’t previously exposed to the product. 

Approval granted by the Saudi FDA to import Microskin into Saudi Arabia is an indicator of the company’s ability to garner attention worldwide.

Microskin have utilised a franchise model to expand the business since 2010, when they opened their first clinic outside Australia at the Laser and Skin Surgery Center of New York.

Each clinic has facilities to undertake computer skin tone matching for patients, as well as training in how to apply the product to their own skin.

For more information visit www.microskin.com.au

19 March 2013

Media Release

Microskin PLC admitted to trade on GXG exchange

BRISBANE, Australia – Microskin PLC, a second skin technology company, announced today that it had been admitted to trading on the GXG Markets OTC immediately under the symbol  MSKN.

The company produces a revolutionary simulated second skin individually formulated to color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin PLC’s wholly owned subsidiary, Microskin International, has already achieved considerable success both in Australia and overseas including establishing franchises in the US, Europe, the Middle East and Indonesia.

Executive chairman, Barry Amor, says admittance to the GXG was a major milestone in the company’s eight-year history.

“We have been at the forefront of the research and development of a second-skin technology which helps people suffering from all sorts of skin conditions,” Mr Amor says.

“It has required a lot of hard work and effort to bring us to where we are now which includes a sizeable international franchise network.

“Being able to trade on an international market will not only give us a more competitive environment for raising capital and trading of shares, but also takes us into a new phase of expansion.”

Microskin appointed first quotation introduction partners Stepping Stone Equity to complete the process.

For more information visit www.microskin.com.au

 

 

Australian second skin technology company to list on UK exchange

Media Release:

27 February 2013

Australian second skin technology company to list on UK exchange
Australian skin simulation technology company Microskin has announced its intention to list
on the UK based GXG exchange.

The company produces a revolutionary simulated second skin individually formulated to
color correct a range of conditions such as dermatitis, eczema, psoriasis and vitiligo.

Microskin has already achieved considerable success both in Australia and overseas
including establishing franchises in the US, Europe, the Middle East and Indonesia.

The Executive Chairman, Barry Amor, says Microskin is now in a position to be able to list on
an exchange, and the GXG offered the best initial option for international expansion.

“Microskin’s listing will provide the necessary capital to support our international expansion
plans, particularly to establish further franchises,” Mr Amor says.

“The GXG is a European regulated market and provides a more competitive environment for
raising capital and trading of shares, especially on a global scale.

“It will also give us access to a much larger consumer base, so all these factors make it an
attractive option to list.”

Microskin has appointed corporate advisors Stepping Stone Equity to complete the process
and to finalise a prospectus to comply with the exchange’s official list, paving the way for a
dual listing on the Frankfurt Stock Exchange.

Mr Amor says Microskin’s successful and profitable track record over the past eight years
has enabled it to build a sizeable franchise network, however liquidity in the company is
required for further expansion.

“While we have achieved considerable domestic and international success to date, we are
now focussing our energies on new markets which will give us a far greater opportunity to
further our expansion plans,” Mr Amor says.

“We are already well underway with negotiations for a number of new franchise agreements
and product development to supplement our flagship offering.

“Our listing strategy will provide us with both the capital and opportunities to continue our
research and development and help to secure our place as a dominant player in our industry
worldwide.”

The listing proposal has already been presented to Microskin shareholders for final approval
and is expected to be completed in the coming days.
For more information or to register interest in Microskin’s listing visit
www.microskin.com.au

ENDS

 

About Microskin

The concept of Microskin, a world-first skin simulation technology, was originally conceived
after realising that make-up was the only method of concealing or camouflaging skin
conditions. What transpired after many years of research into cosmetic chemistry as well as
developing specially designed software used to read human skin, was a system to develop a
spray-on simulated application individually formulated for each client’s skin. Microskin will
not rub off, is completely waterproof, allows the skin to breath and sweat, and lasts for
several days. Since the opening of its first clinic in Brisbane in July 2005, Microskin has
assisted people from all over the world with skin related conditions such as, vitiligo,
birthmarks, burns, eczema, lupus, keloid scarring.

Search
 
Instagram

Info Newsletter!

We respect your email privacy

Email Marketing by AWeber

Quick Links
About us

The concept of Microskin, a world-first skin simulation technology, was originally conceived after we realised that make-up was the only method of concealing or camouflaging skin conditions (more)

Microskin Terms & Conditions

Skin Conditions